Hepalink is the world’s biggest maker of blood-thinning heparin products and a supplier to global drug firms including Sanofi-Aventis (SASY.PA) and Novartis (NOVN.VX).
Hepalink’s current value seems to be about $10.5 billion.
Reuters reported the launch generated a return on paper of more than 200 times for Wall Street Bank Goldman, which bought 45 million Hepalink shares in 2007.
